ALMDP.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 23:35):

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs...

Stats
今日成交量	4 325.00
平均成交量	9 693.00
市值	6.82M
EPS	€0 ( 2024-04-16 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-2.15
ATR14	€0.0130 (0.95%)

Medesis Pharma S.A. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Medesis Pharma S.A. 财务报表

Annual	2022
营收:	€47 297.00
毛利润:	€-2.21M (-4 662.24 %)
EPS:	€-0.630

FY	2022
营收:	€47 297.00
毛利润:	€-2.21M (-4 662.24 %)
EPS:	€-0.630

FY	2021
营收:	€95 729.00
毛利润:	€79 024.00 (82.55 %)
EPS:	€-0.606

FY	2019
营收:	€230 000
毛利润:	€224 000 (97.39 %)
EPS:	€-0.457

Financial Reports:

No articles found.

Medesis Pharma S.A.

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.